TABLE 2.
Cohort demographics and pertinent patient information
| Demographic category | Subcategory | Value for: |
|
|---|---|---|---|
| Pilot | Validation | ||
| No. of cases | 156 | 272 | |
| Age (yrs) | 56 ± 18 | 55 ± 21 | |
| Sex | Male | 67 (43.0%) | 131 (48.2%) |
| Female | 89 (57.0%) | 141 (51.8%) | |
| Race | Caucasian | 137 (87.8%) | 236 (86.8%) |
| Black or African American | 10 (6.4%) | 18 (6.6%) | |
| Asian | 0 (0%) | 4 (1.5%) | |
| American Indian or Alaska Native | 2 (1.3%) | 3 (1.1%) | |
| Native Hawaiian and Pacific Islander | 1 (0.6%) | 0 (0%) | |
| Other or unknown | 6 (3.9%) | 11 (4.0%) | |
| Ribotypes | 027 ribotype | 15 (9.6%) | 25 (9.2%) |
| 014-020 ribotype | 30 (19.2%) | 47 (17.3%) | |
| Method of CDI diagnosis | Toxins A/B enzyme immunoassay | 71 (46%) | 69 (25%) |
| Reflex to PCR for tcdB gene | 85 (54%) | 203 (75%) | |
| Disease measures | IDSA severity | 58 (37.2%) | 71 (26.1%) |
| 30-day mortality | 4 (2.6%) | 19 (7.0%) | |
| DRCs | 10 (6.4%) | 18 (6.6%) | |
| Subset with 30-day all-cause mortality and DRCs | 2 (1.3%) | 14 (5.2%) | |
| Pertinent medical history | Elixhauser score | 4.6 ± 3.3 | |
| Concurrent antibiotics | 112 (71.8%) | 87 (32.0%) | |
| History of C. difficile infection | 40 (25.6%) | 52 (19.6%) | |
| Inflammamatory bowel disease | 41 (15.1%) | ||